Redmile Group

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative and life-altering therapies that address critical unmet medical needs in areas such as transplantation, autoimmune diseases, gene therapy, and oncology. Hansa Biopharma employs a proprietary antibody-cleaving enzyme technology platform to target disease-causing antibodies. Its lead product candidate, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is being explored for potential applications in other organ transplants and acute autoimmune conditions. The company operates primarily in Sweden, other European countries, and the United States, generating most of its revenue from product sales.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

AC Immune is a clinical-stage biopharmaceutical company based in Switzerland, dedicated to developing therapeutic and diagnostic products for neurodegenerative diseases linked to protein misfolding. Utilizing its proprietary technology platforms, the company creates antibodies, small molecules, and vaccines aimed at preventing and modifying these diseases. Its lead candidate, crenezumab, is a monoclonal antibody currently undergoing Phase II clinical trials for Alzheimer’s disease. Other notable candidates include ACI-24, an anti-Abeta vaccine in Phase II trials for Alzheimer’s and Down syndrome, ACI-35, an anti-Tau vaccine that has completed Phase Ib trials, and RG6100, an anti-Tau antibody in Phase II studies for Alzheimer’s patients. Additionally, AC Immune is exploring Tau Morphomer aggregation inhibitor small molecules and has diagnostics targeting various protein aggregates. The company has established collaborations with several prominent organizations, including Genentech and Biogen, and has a research partnership with the University of Pennsylvania focusing on TDP-43 in neurodegenerative diseases. Founded in 2003, AC Immune is headquartered in Lausanne, Switzerland.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Krystal Biotech is a biopharmaceutical company using gene therapy to develop best in class treatments that provide significant clinical benefit for patients suffering from rare debilitating disorders.

Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

Home Biosciences is a European venture builder dedicated to biotech.

Zentera Therapeutics is a biopharmaceutical company.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

Entrada Therapeutics, Inc. is a biotechnology company focused on treating diseases through the intracellular delivery of biologics, such as proteins, peptides, and nucleic acids. Founded in 2016 and based in Boston, Massachusetts, the company aims to transform patient care by developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible. Entrada's technology addresses challenges associated with delivering both large and small molecules, significantly enhancing the efficiency of therapeutic delivery into the cytosol. Its pipeline includes innovative therapies for neuromuscular diseases and other conditions, utilizing proprietary Endosomal Escape Vehicle (EEV) therapeutics to improve treatment outcomes across various organs and tissues.

Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies. Amunix was founded in 2006 and is headquartered in Mountain View, California.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers. Founded in 2017 and based in Rehovot, Israel, the company aims to address genetically defined patient populations by targeting the tumorigenic drivers of cancer. Its lead product candidate, AL101, is an intravenous gamma secretase inhibitor currently undergoing Phase II clinical trials for the treatment of recurrent and metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala is developing AL102, an oral gamma secretase inhibitor, which is in Phase I clinical trials for desmoid tumors and has a collaboration with Novartis to further develop this compound for multiple myeloma. The company's innovative approach combines bioinformatics and next-generation sequencing to deliver targeted therapies to underserved patient populations.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada. It integrates automated pharmacy services into clinics and other healthcare points through its proprietary technology. The company offers comprehensive services via its robotic dispensing platform, the MedAvail MedCenter, and includes home delivery operations. MedAvail primarily operates SpotRx, a telehealth-enabled retail pharmacy that provides remote pharmacist consultations through an on-site dispensing kiosk, catering mainly to Medicare patients in the United States. Additionally, the Pharmacy Technology segment focuses on developing and commercializing the MedCenter for direct sale or lease to third-party customers.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to developing innovative therapies for oncology, addressing unmet medical needs in the treatment of challenging cancers that have not responded to conventional therapies. Founded in 2018 and based in New York, with an additional office in San Francisco, the company has a portfolio of drug development candidates aimed at improving patient outcomes. One of its key clinical-stage candidates is NUV-868, an oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. Additionally, Nuvation Bio is advancing its proprietary small molecule Drug-Drug Conjugate platform, further expanding its therapeutic arsenal in oncology.

Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Nurix Therapeutics is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels to treat cancer and immune disorders. The company's pipeline includes promising preclinical candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeted at relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology applications. Nurix's innovative drug discovery platform, DELigase, leverages its expertise in E3 ligases—enzymes that regulate protein modulation within cells—to identify and advance novel drug candidates. Founded in 2009 and based in San Francisco, Nurix Therapeutics aims to provide effective therapies for challenging diseases through its cutting-edge research and development efforts.

Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies. Amunix was founded in 2006 and is headquartered in Mountain View, California.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Redx Pharma is a UK-based biotechnology company founded in 2010, specializing in drug discovery and development for oncology and fibrotic diseases. The company focuses on creating novel small molecule drugs aimed at addressing significant unmet medical needs. Its product pipeline includes several promising candidates such as RXC004, a porcupine inhibitor in Phase I clinical development for various cancers; ROCK2, targeting diabetic nephropathy and idiopathic pulmonary fibrosis; and RXC005, a reversible inhibitor of Bruton’s tyrosine kinase. Additionally, Redx Pharma collaborates with global pharmaceutical companies, including a research partnership with Jazz Pharmaceuticals to explore drug candidates targeting the Ras/Raf/MAP kinase pathway. The company operates through subsidiaries dedicated to oncology, anti-infectives, and immunology, generating revenue from scientific programs and research collaborations.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company based in New York, dedicated to developing small molecule therapeutics aimed at treating various cancers. Founded in 2014, the company focuses on discovering and advancing drug candidates that target critical biological pathways in cancer. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader currently undergoing Phase I/II clinical trials for advanced or metastatic breast cancer. In addition, Zentalis is developing ZN-c3, an inhibitor of the WEE1 protein tyrosine kinase, for advanced solid tumors; ZN-d5, a selective B-cell lymphoma 2 inhibitor for hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor for advanced non-small cell lung cancer, all of which are also in Phase I/II clinical trials. The company utilizes an integrated discovery engine to identify new chemical entities with the potential for differentiated therapeutic profiles.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company headquartered in Bedford, Massachusetts, focused on developing novel antisense oligonucleotide medicines to address the underlying causes of severe genetic diseases. The company employs its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) technology to enhance gene expression by targeting RNA splicing, thereby selectively restoring protein levels. Its lead product candidate, STK-001, is currently in clinical testing for the treatment of Dravet syndrome, a serious and progressive genetic epilepsy. Established in 2014, Stoke Therapeutics also collaborates with Invitae Corporation to provide genetic testing services, further supporting its mission to advance gene-targeted therapies for patients with severe genetic conditions.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada. It integrates automated pharmacy services into clinics and other healthcare points through its proprietary technology. The company offers comprehensive services via its robotic dispensing platform, the MedAvail MedCenter, and includes home delivery operations. MedAvail primarily operates SpotRx, a telehealth-enabled retail pharmacy that provides remote pharmacist consultations through an on-site dispensing kiosk, catering mainly to Medicare patients in the United States. Additionally, the Pharmacy Technology segment focuses on developing and commercializing the MedCenter for direct sale or lease to third-party customers.

Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered. They have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech.

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focused on developing innovative T cell receptor therapies for cancer treatment. The company's leading product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing phase I/II clinical trials for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another candidate, TC-110, targets CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 leverages extensive expertise in T cell biology to create differentiated therapies that stand apart from traditional CAR-T cell treatments.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies to improve the lives of cancer patients. The company aims to combat drug resistance mechanisms that hinder the effectiveness of existing cancer treatments. Its lead candidate, ripretinib, is designed for gastrointestinal stromal tumors and is also being evaluated in Phase I trials for various other cancers, including gliomas and melanoma. Additionally, Deciphera is advancing other clinical-stage candidates such as DCC-3014, targeting tenosynovial giant cell tumors, and Rebastinib, which is being assessed for solid tumors and in combination with chemotherapy. The company also has a preclinical candidate, DCC-3116, aimed at RAS mutant cancers. Deciphera's proprietary switch-control kinase inhibitor platform underpins its research and development efforts, supporting a diverse pipeline of drug candidates, including QINLOCK, which has received regulatory approval in multiple countries for specific cancer indications.

Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that can deliver highly concentrated, non-aqueous formulations of peptides, proteins, antibodies, and small molecules. These technologies facilitate subcutaneous and intramuscular delivery, offering distinct advantages over traditional formulations, such as eliminating the need for reconstitution and enabling long-term room temperature stability. Xeris currently markets three products: Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. Additionally, the company has an extensive pipeline of development programs aimed at expanding its product offerings through its advanced formulation science.

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that can deliver highly concentrated, non-aqueous formulations of peptides, proteins, antibodies, and small molecules. These technologies facilitate subcutaneous and intramuscular delivery, offering distinct advantages over traditional formulations, such as eliminating the need for reconstitution and enabling long-term room temperature stability. Xeris currently markets three products: Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. Additionally, the company has an extensive pipeline of development programs aimed at expanding its product offerings through its advanced formulation science.

Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based on key insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, founded in 2009. The company focuses on developing small molecule drugs aimed at treating chronic pain and various neurogenic disorders by targeting P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies and is designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy, as well as respiratory and urological issues.

CytomX Therapeutics is an oncology-focused biopharmaceutical company based in South San Francisco, California. The company specializes in developing proteolytically-activated antibody therapeutics using its proprietary Probody technology platform. This innovative approach aims to create cancer immunotherapies that enhance targeting of tumor cells while minimizing effects on healthy tissues. CytomX's clinical-stage product candidates include CX-072, which targets programmed cell death ligand 1; CX-2009, a drug conjugate against CD166; and BMS-986249, a CTLA-4 Probody therapeutic for metastatic melanoma, among others. The company has established strategic collaborations with several major pharmaceutical companies, including AbbVie, Amgen, and Bristol-Myers Squibb, to further the development of its Probody therapeutics. Founded in 2008, CytomX is dedicated to providing patients with more effective and less toxic treatment options for cancer and inflammatory diseases.

Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.

Blueprint Medicines is a biopharmaceutical company dedicated to developing targeted therapies for cancers and rare diseases driven by abnormal kinase activation. Founded in 2008 and based in Cambridge, Massachusetts, the company utilizes its proprietary Insights-to-Validation Platform and chemical library to create small molecule kinase inhibitors that address specific genomic drivers. Key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis, and pralsetinib for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. Additionally, fisogatinib is under investigation for advanced hepatocellular carcinoma, while BLU-782 targets fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with several pharmaceutical companies to enhance its research and development efforts.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada. It integrates automated pharmacy services into clinics and other healthcare points through its proprietary technology. The company offers comprehensive services via its robotic dispensing platform, the MedAvail MedCenter, and includes home delivery operations. MedAvail primarily operates SpotRx, a telehealth-enabled retail pharmacy that provides remote pharmacist consultations through an on-site dispensing kiosk, catering mainly to Medicare patients in the United States. Additionally, the Pharmacy Technology segment focuses on developing and commercializing the MedCenter for direct sale or lease to third-party customers.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with high unmet medical needs. The company is engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia's primary market for its products is the United States, with ongoing efforts to address the needs of targeted patient populations suffering from these conditions.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.